Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

Drayman, Nir; DeMarco, Jennifer K; Jones, Kohar; Azizi, Saara-Anne; Froggatt, Heather M.; Tan, Kemin; Maltseva, N.; Chen, Siquan; Nicolaescu, Vlad; Dvorkin, Steve; Furlong, Kevin; Kathayat, Rahul S.; Firpo, Mason R; Mastrodomenico, Vincent; Bruce, Emily A.; Schmidt, Madaline M; Jedrzejczak, R.; Muñoz-Alía, Miguel Ángel; Schuster, Brooke; Nair, V. P.; Han, Kyu-Yeon; O’Brien, Amornrat; Τοματσίδου, Αναστασία; Meyer, Bjoern; Vignuzzi, Marco; Missiakas, Dominique; Botten, Jason; Brooke, Christopher B.; Lee, Hyun; Baker, Susan C.; Mounce, Bryan C.; Heaton, Nicholas S.; Severson, William; Palmer, Kenneth E.; Dickinson, Bryan C.; Joachimiak, A.; Randall, Glenn; Tay, Savaş

doi:10.1126/science.abg5827

Cited by 202 publications

(186 citation statements)

References 53 publications

Supporting

Mentioning

169

Contrasting

Order By: Relevance

“…Conversely, some MS DMTs could be repurposed to manage COVID-19-associated immune dysregulation. Clinical trials are already ongoing to evaluate IFN-B, fingolimod, dimethylfumarate; additionally, masitinib (a tyrosine-kinase inhibitor that showed efficacy in phase 2B/3 trials for progressive MS) has been recently highlighted as a potent Coronavirus inhibitor (188).…”

Section: Discussionmentioning

confidence: 99%

Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?

et al. 2021

View full text Add to dashboard Cite

Current knowledge on Multiple Sclerosis (MS) etiopathogenesis encompasses complex interactions between the host’s genetic background and several environmental factors that result in dysimmunity against the central nervous system. An old-aged association exists between MS and viral infections, capable of triggering and sustaining neuroinflammation through direct and indirect mechanisms. The novel Coronavirus, SARS-CoV-2, has a remarkable, and still not fully understood, impact on the immune system: the occurrence and severity of both acute COVID-19 and post-infectious chronic illness (long COVID-19) largely depends on the host’s response to the infection, that echoes several aspects of MS pathobiology. Furthermore, other MS-associated viruses, such as the Epstein-Barr Virus (EBV) and Human Endogenous Retroviruses (HERVs), may enhance a mechanistic interplay with the novel Coronavirus, with the potential to interfere in MS natural history. Studies on COVID-19 in people with MS have helped clinicians in adjusting therapeutic strategies during the pandemic; similar efforts are being made for SARS-CoV-2 vaccination campaigns. In this Review, we look over 18 months of SARS-CoV-2 pandemic from the perspective of MS: we dissect neuroinflammatory and demyelinating mechanisms associated with COVID-19, summarize pathophysiological crossroads between MS and SARS-CoV-2 infection, and discuss present evidence on COVID-19 and its vaccination in people with MS.

show abstract

Section: Discussionmentioning

confidence: 99%

Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For these reasons, M pro becomes a high-profile drug target for the development of broad-spectrum antivirals. Structurally disparate compounds including FDA-approved drugs and bioactive compounds have been reported as M pro inhibitors 6 , 7 , 8 , 9 , 10 , several of which also have in vivo antiviral efficacy against SARS-CoV-2 11 , 12 , 13 , 14 , 15 .…”

Section: Introductionmentioning

confidence: 99%

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays

Tan

Choza

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…The uncertainty of the coronavirus disease 2019 (COVID-19) pandemic situation remains elusive, although great success has been accomplished with the rapid development of protective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are currently no effective drugs for the treatment of COVID-19, although clinical trials and case reports involving antiviral and antiparasitic agents have yielded promising results that warrant further investigation [ 1 , 2 ]. Herbal medicines have a long history of vindicated clinical efficacy against infectious diseases.…”

Section: Introductionmentioning

confidence: 99%

Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment

Wang

et al. 2021

Molecules

View full text Add to dashboard Cite

Glycyrrhizic acid (GA), also known as glycyrrhizin, is a triterpene glycoside isolated from plants of Glycyrrhiza species (licorice). GA possesses a wide range of pharmacological and antiviral activities against enveloped viruses including severe acute respiratory syndrome (SARS) virus. Since the S protein (S) mediates SARS coronavirus 2 (SARS-CoV-2) cell attachment and cell entry, we assayed the GA effect on SARS-CoV-2 infection using an S protein-pseudotyped lentivirus (Lenti-S). GA treatment dose-dependently blocked Lenti-S infection. We showed that incubation of Lenti-S virus, but not the host cells with GA prior to the infection, reduced Lenti-S infection, indicating that GA targeted the virus for infection. Surface plasmon resonance measurement showed that GA interacted with a recombinant S protein and blocked S protein binding to host cells. Autodocking analysis revealed that the S protein has several GA-binding pockets including one at the interaction interface to the receptor angiotensin-converting enzyme 2 (ACE2) and another at the inner side of the receptor-binding domain (RBD) which might impact the close-to-open conformation change of the S protein required for ACE2 interaction. In addition to identifying GA antiviral activity against SARS-CoV-2, the study linked GA antiviral activity to its effect on virus cell binding.

show abstract

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

Cited by 202 publications

References 53 publications

Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?

Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays

Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment

Contact Info

Product

Resources

About